EGFR Clinical Trials

18 clinical trials for EGFR across international registries, including 9 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation — RECRUITING · PHASE3
• Targeted Induction Therapy for Stage III Unresectable EGFR Mutant Positive NSCLC — RECRUITING · PHASE2
• A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC — RECRUITING · PHASE1
• Observational Multicenter Study in Patients Receiving Chemotherapy and Amivantamab for Metastatic Non-small Cell Lung Cancer — RECRUITING
• Trilaciclib in Patients Receiving Sacituzumab Tirumotecan for EGFR-mutated, Advanced Non-Small Cell Lung Cancer (NSCLC) — RECRUITING · PHASE2
• Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors — RECRUITING · PHASE1
• Kidney-protective Intervention With Salt Substitute After Kidney Tumor Surgery — RECRUITING · NA
• Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI — RECRUITING · PHASE2
• Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer — RECRUITING · PHASE2
• A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors — COMPLETED · PHASE1
• A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection — ACTIVE_NOT_RECRUITING · PHASE3
• The HER Project: HRD in EGFR-mutated NSCLC — ACTIVE_NOT_RECRUITING
• Real-Time Monitoring of Symptoms in Lung Cancer Patients Receiving Oral Targeted Therapies — ACTIVE_NOT_RECRUITING · NA
• Primary Tumor Resection Plus Osimertinib in Advanced EGFR-mutant Non-small Cell Lung Cancer — NOT_YET_RECRUITING · PHASE2
• Treatment With BIBW 2992, Irreversible Inhibitor of EGFR and HER-2 in Non-small Cell Lung Cancer — COMPLETED · PHASE2
• Development of a Fluorescent Visualization System for Non-visible Lung Cancer Nodules — OTHER · PHASE2
• Almonertinib Plus Metronomic Oral Vinorelbine — OTHER
• To Evaluate the Efficacy and Safety of Gefitinib in Adjuvant Chemotherapy for Lung Adenocarcinoma — OTHER · PHASE3

Refine this search